Phaseline

Targets › ATN1

ATN1 (Atrophin-1): drug programs, companies and trials

1 program from 1 company in 3 trials: 3 Phase 1; Neurology; next expected readout Nov 2026.

Transcriptional corepressor. Recruits NR2E1 to repress transcription. (UniProt, P54259)

Open in Phaseline: the race on ATN1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
n-Lorem FoundationnL-ATN1-002
Antisense oligonucleotide targeting ATN1 mRNA
ATN1Phase 1Dentatorubral-Pallidoluysian AtrophyNov 2026

Conditions

Dentatorubral-Pallidoluysian Atrophy (3)

Modalities

small molecule (1)

Companies

n-Lorem Foundation (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.